THIRD-PARTY TESTING & PURITY
A Certificate of Analysis is supposed to be the final word on what is actually inside a peptide vial or capsule. In practice, the document circulating on many research supplier websites is little more than a formatted PDF with numbers that have never been independently verified. Knowing how to read a legitimate peptide COA — and how to spot a fraudulent one — is one of the most practical skills a research buyer can develop. This guide covers every element that belongs on a credible COA, the three non-negotiable tests, and the specific red flags that should end a supplier relationship before it starts.
A Certificate of Analysis (COA) is a formal document issued by a testing laboratory that records the results of analytical assays performed on a specific batch of compound. In the context of research-grade peptides, a COA serves a straightforward purpose: it provides objective, third-party evidence that the material in question is what the label claims, at the stated purity level, and free from specific classes of contamination that would compromise experimental integrity.
The operative phrase is “third-party.” A COA generated by the same organization that synthesized the peptide is not independent verification — it is self-reporting. Independent verification requires a laboratory with no commercial interest in the outcome, accredited instrumentation, and documented chain-of-custody between the batch and the analytical result. When those elements are present, a COA becomes a meaningful data point. When they are absent, it is marketing collateral dressed as science.
For researchers, the COA also functions as a reproducibility tool. If two different laboratories use the same peptide lot to run parallel experiments, the COA gives them a shared reference point for the compound’s composition. Without batch-level COA data, comparing results across experiments becomes significantly more difficult, because you cannot rule out compound variability as a confounding variable.
You can review Biohacker’s full library of published COAs at our COA page, where every batch is documented and searchable by lot number.
Not all analytical methods are equivalent, and no single test tells the complete story. A rigorous peptide COA requires a minimum of three distinct assay types, each of which answers a different question about the material’s identity, quality, and safety profile.
High-Performance Liquid Chromatography (HPLC) is the standard method for quantifying the purity of a synthesized peptide. The technique works by dissolving the sample in a mobile phase solvent and pushing it through a column packed with a stationary phase material. Different molecular species travel through the column at different rates based on their chemical interactions with the stationary phase. A detector — typically UV absorbance at 214–220 nm, which captures the peptide bond — records a chromatogram: a graph of detector signal versus retention time.
The target compound elutes at a characteristic retention time and produces a peak. All other peaks in the chromatogram represent impurities — synthesis by-products, deletion sequences, oxidized residues, or residual protecting groups from the Fmoc solid-phase synthesis process. Purity is calculated as the area of the target peak divided by the total area of all peaks, expressed as a percentage.
A result of ≥99% HPLC purity means that 99% or more of the UV-absorbing material in the sample is the target compound. The remaining ≤1% represents the aggregate contribution of all detected impurities. This threshold matters because even small amounts of structurally similar impurities can introduce variability into research outcomes. A peptide analogue or truncated sequence that differs by a single amino acid may have substantially different receptor binding characteristics, metabolic stability, or biological activity — none of which would be apparent without high-resolution purity data.
Biohacker’s catalogue averages 99.67% HPLC purity across all batches, a figure that reflects consistent upstream synthesis quality combined with rigorous lot-level testing before any material is made available for research purposes.
What the COA should show: the chromatogram image itself (not just a number), the area integration table listing each peak and its percentage contribution, the column specification, the mobile phase gradient, and the wavelength used for detection. A purity figure without the supporting chromatogram data is unverifiable.
Electrospray Ionization Mass Spectrometry (ESI-MS) is the identity confirmation test that HPLC alone cannot provide. HPLC tells you how pure the sample is; ESI-MS tells you whether the major component is actually the peptide you ordered.
In ESI-MS, the sample is ionized by passing it through a charged electrospray needle, producing multiply-charged ions that are separated by a mass analyzer according to their mass-to-charge ratio (m/z). The resulting mass spectrum shows the molecular mass of the compound with high precision — typically to within 1 Dalton or better.
The test works by comparing the observed molecular weight against the theoretical molecular weight calculated from the peptide’s amino acid sequence. If a peptide has been correctly synthesized — the right sequence, the right molecular formula — the mass spectrum will show a series of multiply-charged ions whose m/z values, when back-calculated, yield a mass consistent with the theoretical value. Any significant deviation indicates a problem: a miscoupled residue, a racemized amino acid, an incomplete deprotection step, or a structurally distinct impurity masquerading as a high-purity sample on the HPLC trace.
This is why HPLC alone is insufficient. It is technically possible to have a sample that shows 99% purity by HPLC but contains the wrong peptide — for example, if a synthesis error produced a compound with similar hydrophobicity to the target, causing it to co-elute at nearly the same retention time. ESI-MS would immediately flag this discrepancy. A COA that lacks mass spectrometry data is missing a fundamental identity check.
The COA should display the observed monoisotopic or average molecular weight, the theoretical molecular weight, and the mass spectrum showing the characteristic charge-state envelope. The deviation between observed and theoretical should be clearly stated and within instrument tolerance.
Endotoxins are lipopolysaccharide (LPS) fragments shed from the outer membrane of gram-negative bacteria. They are extraordinarily potent immunological stimulants: concentrations as low as 0.1 endotoxin units per millilitre (EU/mL) can trigger measurable inflammatory responses in sensitive biological systems. In cell culture, even sub-threshold endotoxin levels can confound assays involving cytokine signalling, NF-κB pathway activation, macrophage function, and numerous other inflammation-adjacent readouts.
The United States Pharmacopeia chapter <85> (USP <85>) defines the standard for endotoxin testing using the Limulus Amebocyte Lysate (LAL) assay or recombinant Factor C (rFC) methods. These tests detect endotoxin at the EU/mL level and are the reference standard for parenteral pharmaceutical products. Research-grade peptides that will be used in cell-based assays or in vivo models should meet a defined endotoxin limit — typically <1.0 EU/mg or lower depending on the application — documented against USP <85> methodology.
A supplier that does not include endotoxin data on the COA is leaving a significant research variable uncontrolled. If a researcher observes an unexpected inflammatory or cell-death signal in a peptide-treated group, and no endotoxin data exists for that lot, ruling out bacterial contamination as the cause requires additional testing that should have been done before the material left the supplier’s warehouse.
Endotoxin testing is also a meaningful proxy for manufacturing hygiene. High endotoxin levels in a synthesized peptide indicate problems with reagent quality, water systems, or handling practices — the same conditions that tend to produce other forms of contamination. A clean endotoxin result is evidence that the manufacturing environment met baseline microbiological standards.
The three analytical tests described above are the scientific core of a peptide COA. But a legitimate document also contains a set of administrative and reference elements that allow the researcher to independently verify the data and trace it back to the specific batch of material they received.
Every COA must carry a unique batch or lot number that directly corresponds to the specific synthesis run being reported. This is not a formatting convention — it is the linking identifier that connects the analytical data to a discrete physical quantity of material. Without a lot number, there is no way to confirm that the data on the document relates to the compound in the container.
The date on which the analytical work was performed matters. Peptides are chemically labile compounds — they can oxidize, aggregate, or degrade over time, particularly under improper storage conditions. A COA dated three years before the purchase date provides limited assurance about the current state of the material. Current-year testing, or testing close to the synthesis date with proper cold-chain documentation, is the standard to look for.